Princy Kumar
Infectious Disease · Washington, DCNPI 1790784957
Payments from drug & device makers
Across 843 payments — averaging $5222.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$982K
- Viiv Healthcare Company$617K
- Theratechnologies Inc.$590K
- Pfizer$588K
- Eli Lilly$555K
- Merck$542K
- plus $528K from 13 others
Across 18 payments — averaging $5480.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$89K
- Amgen$7K
- Gilead$1K
- F. Hoffmann-la Roche AG$853
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 139 | $982,116 |
| Viiv Healthcare Company | 259 | $616,785 |
| Theratechnologies Inc. | 28 | $590,293 |
| Pfizer | 25 | $587,621 |
| Eli Lilly | 11 | $555,196 |
| Merck | 226 | $542,365 |
| Hoffmann-la Roche Limited | 20 | $198,896 |
| Incyte Corporation | 23 | $107,933 |
| GSK | 45 | $77,729 |
| Regeneron | 11 | $39,250 |
| Sanofi Pasteur Inc. | 5 | $30,705 |
| Amgen | 8 | $22,764 |
| Biohaven Pharmaceuticals, Inc. | 4 | $19,939 |
| Shionogi Inc | 10 | $9,336 |
| Seres Therapeutics, Inc. | 4 | $6,850 |
| Janssen Scientific Affairs, LLC | 18 | $5,073 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $3,675 |
| Janssen Products, LP | 4 | $3,010 |
| Aimmune Therapeutics, Inc. | 1 | $3,000 |
How this compares
$4,402,535 in reported general payments places this provider in the 95th percentile of 74 infectious disease providers in District of Columbia.
See all infectious disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Washington
- Theo HodgeWashington$2.5M
- David DiemertWashington$2.3M
- Jesse GoodmanWashington$1.8M
- Jose BordonWashington$1.5M
- Robert GasserWashington$922K
- Marc SiegelWashington$801K
- Deborah GoldsteinWashington$707K
- Glenn WortmannWashington$604K
- Rebecca KumarWashington$497K
- Gary SimonWashington$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.